Bb Biotech Ag Increased By $3.38 Million Its Intra (ITCI) Holding; Seaspan (SSW) Shorts Increased By 6.67%

June 2, 2017 - By Migdalia James

Seaspan Corporation (NYSE:SSW) had an increase of 6.67% in short interest. SSW’s SI was 6.11 million shares in June as released by FINRA. Its up 6.67% from 5.72 million shares previously. With 1.06 million avg volume, 6 days are for Seaspan Corporation (NYSE:SSW)’s short sellers to cover SSW’s short positions. The SI to Seaspan Corporation’s float is 12.81%. About 784,534 shares traded. Seaspan Corporation (NYSE:SSW) has declined 64.89% since June 2, 2016 and is downtrending. It has underperformed by 81.59% the S&P500.

Bb Biotech Ag increased Intra (ITCI) stake by 16.67% reported in 2016Q4 SEC filing. Bb Biotech Ag acquired 225,000 shares as Intra (ITCI)’s stock declined 19.44%. The Bb Biotech Ag holds 1.58 million shares with $23.77 million value, up from 1.35M last quarter. Intra now has $478.22M valuation. The stock declined 0.47% or $0.05 reaching $10.6 on the news. About 112,929 shares traded. Intra-Cellular Therapies Inc (NASDAQ:ITCI) has declined 68.76% since June 2, 2016 and is downtrending. It has underperformed by 85.46% the S&P500.

Since December 6, 2016, it had 3 buys, and 5 sales for $2.89 million activity. Alafi Christopher D bought $1.06M worth of stock or 65,000 shares. 9,375 Intra-Cellular Therapies Inc (NASDAQ:ITCI) shares with value of $142,773 were sold by Vanover Kimberly E.. 65,000 Intra-Cellular Therapies Inc (NASDAQ:ITCI) shares with value of $1.06M were bought by ALAFI MOSHE. 1,601 shares were sold by Halstead Michael, worth $26,497 on Thursday, January 5. $67,541 worth of Intra-Cellular Therapies Inc (NASDAQ:ITCI) shares were sold by Mates Sharon. ALAFI CAPITAL CO LLC also bought $1.06 million worth of Intra-Cellular Therapies Inc (NASDAQ:ITCI) on Tuesday, December 6. Another trade for 1,918 shares valued at $31,800 was made by Hineline Lawrence J. on Thursday, January 5.

Among 9 analysts covering Intra-Cellular Therapies (NASDAQ:ITCI), 5 have Buy rating, 0 Sell and 4 Hold. Therefore 56% are positive. Intra-Cellular Therapies had 18 analyst reports since August 6, 2015 according to SRatingsIntel. On Wednesday, March 9 the stock rating was maintained by JMP Securities with “Market Outperform”. As per Friday, November 6, the company rating was maintained by RBC Capital Markets. As per Thursday, September 29, the company rating was downgraded by JMP Securities. The firm has “Buy” rating by Guggenheim given on Thursday, September 17. As per Friday, August 7, the company rating was upgraded by Zacks. On Thursday, September 29 the stock rating was downgraded by SunTrust to “Neutral”. As per Tuesday, May 2, the company rating was downgraded by Ladenburg Thalmann. The rating was downgraded by Leerink Swann to “Market Perform” on Tuesday, May 2. The firm has “Overweight” rating by Piper Jaffray given on Thursday, June 2.

Investors sentiment increased to 1.46 in 2016 Q4. Its up 0.52, from 0.94 in 2016Q3. It improved, as 25 investors sold ITCI shares while 23 reduced holdings. 27 funds opened positions while 43 raised stakes. 29.52 million shares or 8.32% more from 27.25 million shares in 2016Q3 were reported. Atwood Palmer invested 0% of its portfolio in Intra-Cellular Therapies Inc (NASDAQ:ITCI). Blackrock Fund stated it has 2.03M shares or 0.01% of all its holdings. Rhumbline Advisers accumulated 40,396 shares. Highbridge Cap Mngmt Ltd Co reported 0% stake. Northern Corporation has 406,619 shares. Outfitter Advsr Ltd holds 0.11% or 19,150 shares. Alpine Woods Invsts Lc holds 0.06% in Intra-Cellular Therapies Inc (NASDAQ:ITCI) or 73,944 shares. D E Shaw And Commerce holds 0% or 118,390 shares. Pacad Limited has invested 0.02% of its portfolio in Intra-Cellular Therapies Inc (NASDAQ:ITCI). Sg Americas Securities Ltd Liability Corp invested in 18,608 shares or 0% of the stock. Fiera Capital accumulated 18,320 shares. Thrivent Fin For Lutherans invested in 0% or 49,350 shares. Pictet Asset Ltd invested in 123,108 shares. Citadel Advisors Ltd Llc owns 0.02% invested in Intra-Cellular Therapies Inc (NASDAQ:ITCI) for 1.26M shares. Glenmede Na owns 19,410 shares.

Seaspan Corporation is an independent charter owner and manager of containerships. The company has market cap of $635.59 million. The Firm charters pursuant to long-term, fixed-rate time charters with various container liner companies. It currently has negative earnings. As of February 20, 2017, it had operated a fleet of 88 containerships and had entered into contracts for the purchase of an additional eight new building containerships.